Company Merck & Co., Inc.

MRK

US58933Y1055

Pharmaceuticals

Market Closed - Nyse Other stock markets 04:00:02 2025-12-15 pm EST			5-day change	1st Jan Change
100.26 ^USD	-0.04%		+1.34%	+0.78%

Dec. 15	Merck Poised for Mid-Single-Digit Revenue Growth in Fiscal 2026, BofA Says	MT
Dec. 12	Merck Receives Positive EU Chmp Opinion for Expanded Use of Winrevair?? (Sotatercept) in Adults with Pulmonary Arterial Hypertension (Pah, Who* Group 1 Pulmonary Hypertension)	CI

Business description: Merck & Co., Inc.

Merck & Co., Inc. specializes in the development, production, and marketing of therapeutic products and vaccines sold under prescription. Net sales break down by activity as follows:

- sale of pharmaceutical products (69.4%): for treating hypertension, osteoporosis, atherosclerosis, respiratory, bacterial and fungal, ophthalmologic, and urological diseases, acute migraine, hair loss in men, etc.;

- sale of vaccines (20%);

- sale of animal health products (9.2%);

- other (1.4%).

Net sales are distributed geographically as follows: the United States (50.3%), Europe/Middle East/Africa (21.8%), Latin America (5.4%), China (8.6%), Japan (5.1%), Asia/Pacific (4.8%) and other (4%).

Number of employees: 74,000

Sales by Activity: Merck & Co., Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
Pharmaceutical	43.02B	42.75B	52B	53.58B	57.4B
Animal Health	4.7B	5.57B	5.55B	5.62B	5.88B
Unallocated Other	247M	382M	1.73B	907M	891M
Other	23M	-	-	-	-

See all business segments

Geographical breakdown of sales: Merck & Co., Inc.

Fiscal Period: December	2020	2021	2022	2023	2024
United States	21.03B	22.42B	27.21B	28.48B	32.28B
Europe, Middle East and Africa	13.6B	13.34B	14.49B	13.25B	14.04B
China	3.62B	4.38B	5.19B	6.8B	5.49B
Latin America	2.27B	2.21B	2.58B	3.09B	3.46B
Japan	3.38B	2.73B	3.63B	3.16B	3.28B
Asia Pacific (other than China and Japan)	2.86B	2.41B	3.61B	3.22B	3.06B
Other	1.23B	1.22B	2.57B	2.1B	2.56B

See all geographic segments

Executive Committee: Merck & Co., Inc.

Manager	Title	Age	Since
Robert Davis CEO	Chief Executive Officer	58	2021-06-30
Caroline Litchfield DFI	Director of Finance/CFO	56	2021-03-31
Dave Williams CTO	Chief Tech/Sci/R&D Officer	56	2020-07-31
Peter Dannenbaum IRC	Investor Relations Contact	-	2017-06-30
Joseph Romanelli IRC	Investor Relations Contact	51	1995-12-31

See MERCK & CO., INC. governance

Composition of the Board of Directors: Merck & Co., Inc.

Director	Title	Age	Since
Tom Glocer BRD	Director/Board Member	65	2007-11-26
Patricia Russo BRD	Director/Board Member	72	1995-08-31
Robert Davis CHM	Chairman	58	2022-11-30
Pamela Craig BRD	Director/Board Member	68	2015-08-31
Paul Rothman BRD	Director/Board Member	66	2015-08-31
Inge Thulin BRD	Director/Board Member	71	2018-02-28
Mary Coe BRD	Director/Board Member	57	2019-03-17
Kathy Warden BRD	Director/Board Member	52	2020-03-15
Christine Seidman BRD	Director/Board Member	71	2020-03-15
Risa Lavizzo-Mourey BRD	Director/Board Member	70	2020-05-25

Composition of the Board of Directors

Shareholders: Merck & Co., Inc.

Name	Equities	%	Valuation
Vanguard Fiduciary Trust Co. 10.16 %	252,136,910	10.16 %	26 432 M $
BlackRock Advisors LLC 6.522 %	161,866,866	6.522 %	16 969 M $
STATE STREET CORPORATION 4.761 %	118,180,178	4.761 %	12 389 M $
Wellington Trust Co., NA 3.033 %	75,279,104	3.033 %	7 892 M $
Geode Capital Management LLC 2.409 %	59,798,874	2.409 %	6 269 M $

Name	Equities	%	Valuation
Caixa DTVM SA 0.001119 %	222,130	0.001119 %	3 M $
Safra Asset CTVM SA (Investment Management) 0.000239 %	47,400	0.000239 %	620 444 $
XP Allocation Asset Management Ltda. 0.000026 %	5,130	0.000026 %	67 149 $
E2M Investimentos Ltda. 0.000006 %	1,100	0.000006 %	14 398 $

List of MERCK & CO., INC. shareholders

Holdings: Merck & Co., Inc.

Name	Equities	%	Valuation
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. 8.26%	13,443,693	8.26%	788,083,265 $
PERSONALIS, INC. 15.84%	14,044,943	15.84%	150,702,238 $
MODERNA, INC. 0.59%	2,308,190	0.59%	59,966,776 $
KYMERA THERAPEUTICS, INC. 1.07%	772,165	1.07%	52,414,560 $
ENTRADA THERAPEUTICS, INC. 4.55%	1,739,768	4.55%	17,867,417 $
EVAXION A/S 19.22%	1,214,126	19.22%	7,205,838 $
ALECTOR, INC. 3.25%	3,545,719	3.25%	4,715,806 $
VIRIDIAN THERAPEUTICS, INC. 0.11%	93,414	0.11%	2,985,511 $
XILIO THERAPEUTICS, INC. 2.83%	1,483,758	2.83%	1,124,689 $
SUTRO BIOPHARMA, INC. 0.32%	272,351	0.32%	250,291 $

Company details: Merck & Co., Inc.

Merck & Co., Inc.

126 East Lincoln Avenue

07065, Rahway

+908 740 4000

http://www.merck.com

Group companies: Merck & Co., Inc.

Name	Category and Sector
MSD Sharp & Dohme GmbH MSD Sharp & Dohme GmbH Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes pharmaceutical products & vaccines	Pharmaceuticals: Major
Merck Sharp & Dohme LLC Merck Sharp & Dohme LLC Operates as a pharmaceutical company
Merck Sharp & Dohme LLC Merck Sharp & Dohme LLC Operates as a pharmaceutical company
MSD Finance BV MSD Finance BV MiscellaneousMiscellaneous Functions as an investment holding company	Miscellaneous
Merck Sharp & Dohme Finance Europe Ltd. Merck Sharp & Dohme Finance Europe Ltd. Miscellaneous Commercial ServicesCommercial Services Provides business support services	Miscellaneous Commercial Services

See all subsidiaries

Other Pharmaceuticals

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5d. change	1-year change	3-years change	Capi.($)
MERCK & CO., INC.	-0.04%	+1.34%	-1.71%	-8.55%	249B
ELI LILLY AND COMPANY	+3.38%	+6.48%	+34.60%	+195.04%	951B
JOHNSON & JOHNSON	+1.22%	+6.22%	+46.07%	+20.67%	516B
ABBVIE INC.	+1.85%	+1.94%	+31.19%	+39.45%	402B
ROCHE HOLDING AG	+0.75%	+1.32%	+27.13%	+6.43%	346B
ASTRAZENECA PLC	+0.24%	+1.34%	+30.88%	+23.47%	282B
NOVARTIS AG	+1.17%	+0.56%	+22.22%	+26.73%	259B
NOVO NORDISK A/S	+0.06%	+6.48%	-59.01%	-31.31%	221B
AMGEN INC.	+2.38%	+1.27%	+20.21%	+22.23%	175B
GILEAD SCIENCES, INC.	-0.51%	-1.16%	+30.40%	+38.35%	149B
Average	+0.44%	+2.40%	+18.20%	+33.25%	355.01B
Weighted average by Cap.	+0.14%	+3.52%	+24.69%	+64.32%